# Perceive Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/perceive-pharma

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Total disclosed funding: $15M
- Latest round: Series A (Feb 18, 2025)
- Investors on record: 6

## About

Founded in 2023 and based in California, US, Perceive Pharma, Inc. is a biotechnology company that provides pharmaceutical novel small molecule therapeutics. The firm is a spin-off from Perceive Biotherapeutics. In February 2025, Perceive Pharma, Inc. raised USD 15 million in series A funding from new investors Braidwell, Catalio Capital Management, Deerfield Management, Johnson & Johnson Innovation, GV, and Retinal Degeneration Fund. The firm as of February 2025, is eld by its founder and President, Anne (Brody) Rubin.

The company focused on developing novel small molecule neuroprotective therapeutics for ophthalmic diseases, with a particular emphasis on glaucoma. The company’s primary focus is to leverage its proprietary screening technology to identify neuroprotective pathways and develop therapies that address unmet needs in ophthalmology. Its lead candidate, PBI-671, targets glaucoma, an eye condition affecting millions, including many with normal intraocular pressure.

The company plans to utilize the February 2025 funding to advance ophthalmic neuroprotection development, support glaucoma therapeutic programs, expand preclinical research, and strengthen clinical readiness.

## Funding rounds

- Series A, Feb 18, 2025, $15M — Johnson & Johnson Innovation, GV, Deerfield Management, Catalio Capital Management, Braidwell, Retinal Degeneration Fund

## Investors

- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A
- GV (https://capitalatlas.ai/funds/gv) — Series A
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series A
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series A
- Braidwell (https://capitalatlas.ai/funds/braidwell) — Series A
- Retinal Degeneration Fund (https://capitalatlas.ai/funds/retinal-degeneration-fund) — Series A